

QlosiTM (pilocarpine HCl ophthalmic solution) 0.4%

GIVE MORE PRESBYOPES A CHANCE TO SEE CLEARLY¹

It's time to start THE QLOSI CHAT



Help patients understand why you're recommending Qlosi and how to achieve treatment success with these talking points:

Qlosi is my first choice for your first presbyopia drop

Qlosi was designed to clear blurry near vision while providing exceptional comfort

- Improves the eye's natural ability to focus on nearby objects/small details¹
- Designed for comfort with the EyeQ Formulation^{TM1-3}
 - Lowest effective concentration of active ingredient, includes dual lubricating agents (HA & HPMC), near-neutral pH, and preservative-free
- Most side effects are mild and occurred in fewer than 1 out of 10 patients⁴

In multiple studies, Qlosi proved it helps people have clearer near vision in bright or dim light with no impact on distance vision for most people^{1,4}

Week One: 2 doses a day for best results

The Qlosi Clear Start Week is the first 7 days of treatment that helps your eyes get used to their new ability to see up close^{1,4}

- Each dose is taken as 1 drop per eye¹
- 2-3 hours after the first dose, take a second dose¹
- Fill your prescription to receive the rest of your doses before completing 5 days of treatment with the Starter Pack*

Taking 2 doses of Qlosi every day for the first week helps you achieve the best clear near vision possible⁴

*Qlosi Starter Pack includes 10 vials (2 daily doses for 5 days of treatment).

Qlosi™ dosing helps keep you in control of your vision

Dosing flexibility allows Qlosi to adapt to your day¹

- The first dose works for up to 3 hours
- For up to 8 hours of clearer near vision, take a second dose 2-3 hours after the first dose
- Wait at least 10 minutes after using Qlosi before putting your contact lenses back in

With convenient on-demand dosing, you can choose when to use Qlosi



Start the Qlosi Chat so your patients can say goodbye to, “*Can you read this for me?*”

Clarity starts with Qlosi



Indication and Usage

Qlosi™ is indicated for the treatment of presbyopia in adults.

Important Safety Information

CONTRAINDICATIONS

Hypersensitivity

WARNINGS AND PRECAUTIONS

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

QLOSI is not recommended to be used when iritis is present.

QLOSI should not be administered while wearing contact lenses. Remove lenses prior to the installation of QLOSI and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

ADVERSE REACTIONS

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Please see full Prescribing Information here: <https://www.qlosi.com/prescribing-information>

©2025 Orasis Pharmaceuticals, Inc. All Rights Reserved.
QLO.00410 | 10/2025

References: 1. Qlosi [package insert]. Ponte Vedra, FL. Orasis Pharmaceuticals. 2. Vuity PI [package insert]. North Chicago, IL: AbbVie Inc. 3. VIZZ [prescribing information]. Solana Beach, CA; LENZ Therapeutics, Inc. 4. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. *Clin Ther*. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005